Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering...Read More
Phanes' three technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties.
PACbodyTM: Build native IgG-like bispecific antibodies.
ATACCbodyTM: Build bispecific antibodies with modulated activities.
SPECpairTM: Build bispecific antibodies with enhanced manufacturability.